Navigation Links
Advanced Prenatal Therapeutics Appoints Dr. Nihar Nayak to its Scientific Advisory Board
Date:7/29/2013

LAGUNA HILLS, Calif., July 29, 2013 /PRNewswire/ -- Advanced Prenatal Therapeutics, Inc. (APT), a private company developing the first medical device specifically designed to treat preeclampsia, is happy to announce the appointment of its first scientific advisor: Nihar Nayak, PhD, DVM. Dr. Nayak brings to the table over 16 years of research experience and a passion for the development of novel products to treat preeclampsia.

Dr. Nayak is an Associate Professor of Obstetrics and Gynecology (Research) and the Director of Translational Research in the Division of Maternal Fetal Medicine at Stanford University School of Medicine. As a key scientific leader in the prenatal field with extensive expertise in translational research, Dr. Nayak will offer APT a valuable perspective on product development and study design.

"His prior work with sFlt-1 and his expertise in translational research make him exceptionally valuable as an advisor and research collaborator," explains Dr. James Smith, CEO and President of APT. "Dr. Nayak's affiliation with Stanford's world-class research and clinical environment provides us with extraordinary resources and opportunities to advance our product commercialization efforts."

One of Dr. Nayak's major research goals is to understand the uterine mechanisms that affect blood vessel development during preeclampsia and to facilitate the translation of cutting edge research into new therapies. "Preeclampsia, a leading cause of prematurity and maternal and fetal death, is a completely unmet medical need," explains Dr. Nayak. "Research and development using therapeutic targets like sFlt-1 and other circulating factors could open the door to much needed therapies for preeclampsia patients."

Dr. Nayak has received several research awards, including the Lalor Foundation postdoctoral fellowship, the Andrew Mellon Foundation Junior Investigator Award, and the NIH BIRCWH award. Recently, Dr. Nayak also received a Vision Grant from the Preeclampsia Foundation to study the role of placental proteins in preeclampsia with a focus on sFlt-1 and vascular endothelial growth factor VEGF, the biomarkers affected by APT's initial product development efforts.

About Advanced Prenatal Therapeutics, Inc. (www.advancedprenatal.com) Advanced Prenatal Therapeutics, Inc.'s mission is to develop treatments for preeclampsia that will safely prolong pregnancy. To accomplish this goal, APT is developing a novel therapeutic device for preeclampsia that specifically removes disease-causing factors from the mother's blood. This press release may contain forward-looking statements. There can be no assurance that development efforts will succeed, or that the novel therapeutic products will receive regulatory clearance, or achieve commercial success.

Investor Relations:
Dan Thiel
Advanced Prenatal Therapeutics, Inc.
949.340.7261
dthiel@advancedprenatal.com


'/>"/>
SOURCE Advanced Prenatal Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis
2. Advanced Circulatory Selects Combat Medical Systems As Its Exclusive Sales Distributor for Military and Federal Market in US
3. WebPAX v8 - The fastest, most technologically advanced zero-footprint medical image viewer yet
4. New RCSA Certification Curriculum Uses Angio Mentor Simulators for Advanced Training
5. JDRF Announces Two Partnerships to Develop Stable, Pumpable Glucagon to Support Advanced Generation Artificial Pancreas Systems
6. NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinsons Disease
7. Belrose Pharma Acquires Enzons Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies
8. New drug proving effective in attacking advanced prostate cancer
9. Ochsner Health System Improves Safety Through Advanced Medication Management Technology
10. Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
11. New Air Products Microsite Features Advanced Liquid Nitrogen Solutions for the Chemical, Pharmaceutical, and Life Science Industries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... Diplomat Pharmacy, Inc. (NYSE: DPLO) is pleased ... Pharm D., to Vice President of Education and Quality. ... will continue to lead and oversee Diplomat University, an ... and training to Diplomat employees and external professionals on ... also houses the quality assurance department, which focuses on ...
(Date:4/26/2016)... 2016 US demand for infection prevention ... percent annually to $27.6 billion in 2020.  Increasing ... decrease rates of healthcare-associated infections (HAIs) will boost ... services.  Although declining, the overall rate of certain ... set by the CDC.  Recent statistics indicate that ...
(Date:4/26/2016)... DUBLIN , April 26, 2016 ... "Financial Assessment and Credit Risk Analysis of the Biological ... This comprehensive report analyzes the financial assessment ... China . The report provides readers ... key topics all market participants should be aware of. ...
Breaking Medicine Technology:
(Date:4/28/2016)... , ... April 28, 2016 , ... La Sirena Foods ... one in Central America and is looking to grow their market share in the ... an exceptional brand as La Sirena Foods and indirectly with Otis ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... today the open availability of a new CDISC standard, Clinical Trial Registry ... clinical trials. This innovative standard will make it possible to build applications ...
(Date:4/28/2016)... West Palm Beach, FL (PRWEB) , ... April 28, 2016 , ... ... time for the spring season. Smart pots are frequently used by professional organic farmers ... time for growers to order their supply of fabric pots. Our goal is to ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... enterprise Data Center Infrastructure Management solutions, announces today the availability of its ... in the area of capacity management and optimization, providing new analytical capabilities ...
(Date:4/28/2016)... ... April 28, 2016 , ... USA Medical Card reminds us that May is National Stroke Awareness ... the fourth leading cause of death in the United States; someone has one every 40 ... them in individuals under 65 years old. A stroke is when blood flow to ...
Breaking Medicine News(10 mins):